Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1031-1041

  De Sousa Mendes, Maïlys ^a   Hirt, Deborah ^a,b   Urien, Saik ^a,c   Valade, Elodie ^a   Bouazza, Naïm ^a   Foissac, Frantz ^a   Blanche, Stephane ^a,d   Treluyer, Jean Marc ^a,b   Benaboud, Sihem ^a,b  

^a Clinique Paris Centre   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

emtricitabine; lamivudine; PBPK; pharmacokinetics; pregnancy; tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; TENOFOVIR; ANTIRETROVIRUS AGENT;

AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; INTRINSIC CLEARANCE; KIDNEY TUBULE EXCRETION; MAXIMUM PLASMA CONCENTRATION; ORAL CLEARANCE; PHARMACOKINETICS; PREDICTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RENAL CLEARANCE; URINARY EXCRETION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADULT; BIOLOGICAL MODEL; COMPUTER SIMULATION; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; COMPUTER SIMULATION; EMTRICITABINE; FEMALE; HUMANS; LAMIVUDINE; MIDDLE AGED; MODELS, BIOLOGICAL; PREGNANCY; RENAL ELIMINATION; TENOFOVIR; YOUNG ADULT;

EID: 84946495841     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12685     Document Type: Article

References (47)

1. UNAIDS. UNAIDS 2013 [Internet]. Global report 2013. 2013. Available at http://www.unaids.org/en/resources/documents/2013/ (last accessed 17 December 2013).
2. WHO | Guidelines: HIV [Internet]. WHO. 2013. Available at http://www.who.int/hiv/pub/guidelines/en/ (last accessed 30 July 2014).
3. Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD,. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol 2014; 54: 53-69.
4. Anderson GD,. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
5. Luecke RH, Wosilait WD, Pearce BA, Young JF,. A computer model and program for xenobiotic disposition during pregnancy. Comput Methods Programs Biomed 1997; 53: 201-24.
6. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD,. A PBPK Model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the sSite of CYP3A induction. CPT Pharmacomet Syst Pharmacol 2012; 1: e3.
7. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD,. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos Biol Fate Chem 2013; 41: 801-13.
8. Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A,. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4: PBPK for pregnancy with time-varying physiological parameters. Br J Clin Pharmacol 2012; 74: 873-85.
9. Gentry PR, Covington TR, Andersen ME, Clewell HJ III,. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 2002; 36: 51-68.
10. Isoherranen N, Thummel KE,. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 2013; 41: 256-62.
11. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD,. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19: PBPK prediction of PK changes during pregnancy. Br J Clin Pharmacol 2014; 77: 554-70.
12. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H,. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51: 365-96.
13. Kearney BP, Flaherty JF, Shah J,. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612.
14. Janneh O, Khoo S,. Interactions of tenofovir, lamivudine, abacavir and didanosine in primary human cells. Pharmaceutics 2011; 3: 326-37.
15. Kuklenyik Z, Martin A, Pau C-P, Garcia-Lerma JG, Heneine W, Pirkle JL, Barr JR,. Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J Chromatogr Sci 2009; 47: 365-72.
16. (R) oral tablets, tenofovir disoproxil fumarate oral tablets. 2010.
17. Lee WA, He G-X, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC,. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49: 1898-906.
18. ViiV Healthcare Shire Canada. monographie Heptovir,lamivudine [Internet]. 2011 [cité 21 janv 2014]. Disponible sur: http://www.gsk.ca/french/docs-pdf/product-monographs/Heptovir.pdf
19. Van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA,. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS Lond Engl 1992; 6: 1471-5.
20. (R), lamivudine. 2002.
21. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE,. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66.
22. (TM), emtricitabine capsules. 2003.
23. Hirt D, Urien S, Rey E, Arrive E, Ekouevi DK, Coffie P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Treluyer J-M,. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2008; 53: 1067-73.
24. Rodgers T, Rowland M,. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-57.
25. Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D,. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother 2012; 56: 776-82.
26. Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, Bouazza N, Foissac F, Chappuy H, Urien S, Treluyer JM,. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2011; 56: 857-62.
27. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, Cundy KC,. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14: 1824-9.
28. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO,. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-\infected adults. Antimicrob Agents Chemother 1998; 42: 2380.
29. Gish RG, Leung NWY, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F,. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 1734-40.
30. Gagnieu M-C, Barkil ME, Livrozet J-M, Cotte L, Miailhes P, Boibieux A, Guitton J, Tod M,. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 2008; 48: 1282-8.
31. Jullien V, Tréluyer J-M, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S,. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005; 49: 3361-6.
32. Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P, Lertora J, Kiesewetter D,. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother 2009; 53: 4086-95.
33. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y,. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71: 619-27.
34. Klaassen CD, Aleksunes LM,. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010; 62: 1-96.
35. Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA,. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 2012; 64: 803-33.
36. Klein DM, Evans KK, Hardwick RN, Dantzler WH, Wright SH, Cherrington NJ,. Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1. J Pharmacol Exp Ther 2013; 346: 121-9.
37. Huwaldt J,. A plot digitizer [Internet]. 2010. Available at http:\\plotdigitizer.sourceforge.net (last accessed 4 April 2014).
38. Wang LH, Begley J, St. Claire RL 3rd, Harris J, Wakeford C, Rousseau FS,. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20: 1173-82.
39. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M,. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52: 3253-8.
40. Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron JJ Jr, Bartlett JA,. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 1999; 43: 3025-9.
41. Valade E, Tréluyer J-M, Dabis F, Arrivé E, Pannier E, Benaboud S, Fauchet F, Bouazza N, Foissac F, Urien S, Hirt D,. Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. Br J Clin Pharmacol 2014; 78: 1378-86.
42. Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltõ J, Burger DM,. PANNA network. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS Lond Engl 2013; 27: 739-48.
43. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M,. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med avr 2012; 13: 226-35.
44. Xia B, Heimbach T, Gollen R, Nanavati C, He H,. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pPregnancy. AAPS J 2013; 15: 1012-24.
45. Benet LZ, Hoener B,. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21.
46. Buist SCN, Cherrington NJ, Choudhuri S, Hartley DP, Klaassen CD,. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 2002; 301: 145-51.
47. Yacovino LL, Aleksunes LM,. Endocrine and metabolic regulation of renal drug transporters. J Biochem Mol Toxicol 2012; 26: 407-21.